Medicare Part D coverage · 1.5 · RxCUI 2056700
1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy]
Per the CMS 2026 Part D formulary file, 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy] is covered by 138 Medicare Part D plans (2.7% of enrollable products), averaging Tier 2.9, with prior authorization required on 62.5% of covering formularies.
- 2.7%
- Plan coverage
- 138
- Plans covering
- T2.9
- Avg tier
- 62.5%
- Prior auth required
What the CMS Formulary Data Shows for 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy]
Per the CMS 2026 Part D formulary file, 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy] (RxNorm concept RXCUI 2056700, generic name 1.5) appears on 8 distinct formulary files spanning 138 Medicare Part D plan offerings - 2.7% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.9.
Real-world access to 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy] depends on utilization management as much as tier placement: 62.5% of covering formularies require prior authorization. 0% require step therapy. 50% apply quantity limits.
Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy] today.
Coverage Details
- Formularies covering
- 8
- Plans covering
- 138
- Coverage rate
- 2.7%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 62.5% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 50% of formularies
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy] covered by Medicare Part D?
Yes, 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy] is covered by 138 Medicare Part D plans (2.7% of all Part D formularies).
What tier is 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy] on Medicare Part D plans?
1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy] averages Tier 2.9 across Part D plans, ranging from Tier 1 to Tier 4.
Does 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy] require prior authorization?
62.5% of Part D formularies require prior authorization for 1.5 ML fremanezumab-vfrm 150 MG/ML Prefilled Syringe [Ajovy]. Step therapy: 0%. Quantity limits: 50%.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
Similar prior-authorization rate
- deferiprone 1000 MG Oral Tablet [Ferriprox] 62.5% PA
- trientine hydrochloride 500 MG Oral Capsule 62.5% PA
- dihydroergotamine mesylate 0.5 MG/ACTUAT Metered Dose Nasal Spray 62.5% PA
- cysteamine 150 MG Oral Capsule [Cystagon] 62.3% PA
- alosetron 1 MG Oral Tablet 62.8% PA
- alosetron 0.5 MG Oral Tablet 62.8% PA